Oleunor Mit Elektrolyten (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Oleunor Mit Elektrolyten provides amino acids that participate in multiple metabolic pathways and may be used in clinical nutrition contexts.

• Protein‑energy malnutrition: helps restore nitrogen balance and support tissue repair.
• Post‑operative recovery: contributes to wound healing and muscle preservation.
• Chronic kidney disease management: offers a controlled source of amino acids to limit nitrogen waste.
• Critical‑illness nutrition: assists in maintaining lean body mass during intensive care.
• Metabolic disorders: supports patients with inherited amino‑acid metabolism deficiencies.

• The amino acids in Oleunor Mit Elektrolyten are absorbed in the gastrointestinal tract and enter systemic circulation, where they serve as substrates for protein synthesis, act as precursors for neurotransmitters and hormones, and participate in the urea cycle and energy‑producing pathways such as the citric acid cycle.

Adverse reactions are generally uncommon for oral amino‑acid mixtures, but they can occur.

Common Side Effects

• Nausea: mild stomach upset after ingestion.
• Diarrhea: loose stools, especially with high‑dose regimens.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Headache: mild, self‑limiting headache.
• Skin reddening: mild flushing or erythema.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Hyperammonemia: elevated blood ammonia in susceptible individuals.
• Metabolic imbalance: disturbances in electrolyte or acid‑base status.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Renal impairment worsening: increased serum creatinine in patients with pre‑existing kidney disease.
• Severe gastrointestinal bleeding: rare but possible with ulcerative conditions.

When considering Oleunor Mit Elektrolyten, clinicians should evaluate patient‑specific factors and monitor relevant parameters.

• Renal function: assess baseline creatinine and adjust use in severe impairment.
• Hepatic status: avoid in active liver disease without monitoring.
• Pregnancy and lactation: limited data; use only if benefits outweigh risks.
• Drug interactions: review concomitant medications that affect amino‑acid metabolism.
• Metabolic disorders: caution in patients with inborn errors of metabolism.

Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Oleunor Mit Elektrolyten may influence the pharmacokinetics or pharmacodynamics of certain medicines.

Major Interactions (Avoid)

• Antiepileptic drugs: may alter plasma levels of valine and leucine.
• L‑Arginine supplements: excessive combined dosing can affect nitric oxide pathways.

Moderate Interactions (Monitor Closely)

• Insulin or oral hypoglycemics: amino acids can stimulate insulin release, requiring glucose monitoring.
• Diuretics: may increase renal loss of electrolytes when combined with high amino‑acid loads.
• Warfarin: protein intake changes can modify INR stability.
• Thyroid hormone replacement: high protein loads may affect absorption.
• Carnitine supplements: competition for renal tubular transport.